Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2025 07:30 ET | Source: Attovia Therapeutics, Inc.

Attovia Therapeutics Announces $90 Million Series C Financing to Advance ATTOBODY-based Programs through Clinical Proof of Concept

Series C round led by Deep Track Capital with participation from additional new and existing investors Financing will fund early-to-mid-stage clinical studies for ATTO-1310 in chronic pruritus and...
January 23, 2025 07:30 ET | Source: Attovia Therapeutics, Inc.

Attovia Therapeutics Announces First Participant Dosed in First-in-Human Phase 1 Study of ATTO-1310, its Novel Half-life Extended Anti-IL-31 ATTOBODY for the Treatment of Chronic Pruritus

ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for best-in-disease efficacy across pruritic conditions First drug...
July 12, 2021 05:33 ET | Source: Research and Markets

Ulcerative Colitis Clinical Landscape Report 2021: Pipeline Holds Multiple Novel Prospects in Terms of Distinct Mechanisms of Action and Biologics

Dublin, July 12, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Ulcerative Colitis" report has been added to ResearchAndMarkets.com's offering. UC typically presents with bloody diarrhea, which may...